Observational analysis reveals lymphocyte count predicts MSC proliferation in cardiac patients, suggesting personalized therapy may enhance differentiation.
Abstract Patient-specific factors critically influence the therapeutic potential of bone marrow-derived mesenchymal stem cells (BM-MSCs) for cardiac regeneration. In this work, we identify lymphocyte count as a key clinical predictor of BM-MSC proliferative capacity, with coronary artery disease significantly delaying expansion in patients undergoing cardiac surgery. Thus, we established cell selection criteria for patient-derived MSCs for further differentiation into cardiomyocytes. To overcome the limitations of MSCs in cardiac differentiation, we developed a novel protocol using conditioned medium mimicking patient-specific in vivo conditions from iPSC-derived cardiomyocytes (iPSC-CM). This approach successfully generated functional cardiomyocytes from patient-specific BM-MSCs, as evidenced by spontaneous calcium transitions, structural maturation, and electrophysiological activity. Our results provide a unique protocol for inducing MSC differentiation for cell therapy from patient selection to patient-specific personalized preparation as a differentiation strategy.
No takes yet. Share an insight, caveat, or question.
Al-Khateeb et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: